| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 04/28/2004 | EP1412371A1 IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
| 04/28/2004 | EP1411990A2 Modulation of antibody formation in mammals, applicability in gene therapy and animal model generation |
| 04/28/2004 | EP1411989A2 Methods for improving cell line activity in immunoisolation devices |
| 04/28/2004 | EP1411979A1 Vaccine comprising gp120 and nef and/or tat for the immunisation against hiv |
| 04/28/2004 | EP1411971A1 Use of long pentraxin ptx3 for treating female infertility |
| 04/28/2004 | EP1411970A2 Use of sarp-1 for the treatment and/or prevention of scleroderma |
| 04/28/2004 | EP1411966A2 Method for treating secondary tissue degeneration associated with central nervous system injury |
| 04/28/2004 | EP1411898A1 Pharmaceutical composition comprising lipids with a polar and a nonpolar moiety |
| 04/28/2004 | EP1411897A2 Compositions and methods for intracellular delivery |
| 04/28/2004 | EP1411880A2 Recombinant vsv for the treatment of tumor cells |
| 04/28/2004 | EP1411770A2 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 04/28/2004 | EP1382688A9 Screening method |
| 04/28/2004 | EP1286684B1 use of cxcr4 antagonists for treating autoimmune diseases and cancer |
| 04/28/2004 | EP1259190B1 Method for making, loading and sealing a cell or drug encapsulation device, and such a device |
| 04/28/2004 | EP1255559B1 Use of inhibitors of caspase-3 or caspase-activated desoxyribonuclease (cad) for treating cardiac disease |
| 04/28/2004 | EP1198489B1 Combinations for introducing nucleic acids into cells |
| 04/28/2004 | EP1084232B1 Genetically-modified fibroblasts and the use thereof |
| 04/28/2004 | EP0910645B1 A KINASE CAPABLE OF SITE-SPECIFIC PHOSPHORYLATION OF I-kappa-B-alpha |
| 04/28/2004 | EP0840741B1 Pna-dna chimeras and pna synthons for their preparation |
| 04/28/2004 | EP0787201B1 Poly(organo)phosphazenes for use in synthetic transfection systems |
| 04/28/2004 | CN1492927A Human FGF23 protein mutant lowering blood phosphorus level |
| 04/28/2004 | CN1492926A Preferred segments of neural thread protein and methods of using the same |
| 04/28/2004 | CN1492876A Amphoteric sterols and the use thereof |
| 04/28/2004 | CN1492875A TTK in diagnosis and as a therapeutic target in cancer |
| 04/28/2004 | CN1147587C Method of strengthening specific destination gene expression of cell |
| 04/28/2004 | CN1147584C Modulators of tissue regeneration |
| 04/28/2004 | CN1147505C G-protein receptor HTNAD 29 |
| 04/28/2004 | CN1147472C Benzamide formulation with histone deacetylase inhibitor activity |
| 04/28/2004 | CA2447199A1 Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances |
| 04/28/2004 | CA2447190A1 Homing of donor cells to a target zone in tissue using active therapeutics or substances |
| 04/28/2004 | CA2447167A1 Homing of autologous cells to a target zone in tissue using active therapeutics or substances |
| 04/27/2004 | US6727353 Nucleic acid encoding Kv10.1, a voltage-gated potassium channel from human brain |
| 04/27/2004 | US6727239 Inhibitory activity on no- synthase enzymes producing nitrogen monoxide no and/or an activity which traps the reactive oxygen species (ros) |
| 04/27/2004 | US6727225 TWEAK receptor |
| 04/27/2004 | US6727064 Antiinflammatory agents; anticarcinogenic agents |
| 04/27/2004 | US6727058 Transfecting cell with first polynucleotide comprising retroviral genome operably linked to first inducible transcription regulation element wherein retroviral genome is defective for self-replication, second, third polynucleotides |
| 04/27/2004 | US6726926 Disaccharide protector; frozen; preserved for longer than one year; shows excellent restoration ability in water |
| 04/27/2004 | US6726907 Purified adenoviral compositions |
| 04/27/2004 | US6726860 Production scale method of forming microparticles |
| 04/25/2004 | CA2446662A1 Plasmodium falciparum virulence factor var o |
| 04/25/2004 | CA2409897A1 Plasmodium falciparum virulence factor var o |
| 04/22/2004 | WO2004033723A2 Neurodegenerative disease-associated gene |
| 04/22/2004 | WO2004033696A2 Recombinant adenoviral vectors and applications thereof |
| 04/22/2004 | WO2004033690A1 Novel full-length genomic rna of japanese encephalitis virus, infectious jev cdna therefrom, and use thereof |
| 04/22/2004 | WO2004033664A2 Circular dna molecule having a conditional origin of replication, process for their preparation and their use in gene therapy |
| 04/22/2004 | WO2004033653A2 Gene regulation with aptamer and modulator complexes for gene therapy |
| 04/22/2004 | WO2004033634A2 Transgenic cells transfected with pituitary tumor transforming gene (pttg) expression vectors and uses therefor |
| 04/22/2004 | WO2004033620A2 Methods and compositions for therapeutic use of rna interference |
| 04/22/2004 | WO2004033618A2 Stabilized naked dna compositions |
| 04/22/2004 | WO2004033614A1 Molecule-releasing apparatus and molecule-releasing method |
| 04/22/2004 | WO2004032974A1 Process for generating multilayered particles |
| 04/22/2004 | WO2004032973A2 Use of sns insulator of sea urchin for the gene therapy of erythroid cell diseases |
| 04/22/2004 | WO2004032880A2 Method for inhibiting angiogenesis with ship-1 inhibitors |
| 04/22/2004 | WO2004032877A2 Compositions, organisms and methodologies employing a novel human kinase |
| 04/22/2004 | WO2004032867A2 Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use |
| 04/22/2004 | WO2004032860A2 Hiv vaccine formulations |
| 04/22/2004 | WO2004032622A2 Production of peptides in plants as viral coat protein fusions |
| 04/22/2004 | WO2004032614A2 Animal with modification of cytoplasmic dynein heavy chain 1 gene |
| 04/22/2004 | WO2004020639A3 Production of multimeric fusion proteins using a c4bp scaffold |
| 04/22/2004 | WO2004019906A3 Method of manufacturing albumin microspheres comprising antisense oligonucleotides (oligomers) to nf-kb |
| 04/22/2004 | WO2004018506A3 Inducible alphaviral/orip based gene expression system |
| 04/22/2004 | WO2004005544A3 Marker genes for determining renal toxicity |
| 04/22/2004 | WO2004003201A3 Antisense modulation of lrh1 expression |
| 04/22/2004 | WO2003088812A3 Nor-1 and nur77 nuclear receptors as targets for anti-leukemia therapy |
| 04/22/2004 | WO2003064625A3 Oligonucleotide compositions with enhanced efficiency |
| 04/22/2004 | WO2003057164A3 Compounds for delivering substances into cells |
| 04/22/2004 | WO2003051272A9 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR GnRH-I AND GnRH-II MODULATION OF T-CELL ACTIVITY, ADHESION, MIGRATION AND EXTRAVASATION |
| 04/22/2004 | WO2003046506A3 Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies |
| 04/22/2004 | WO2003040345A3 Type 2 cytokine receptor and nucleic acids encoding same |
| 04/22/2004 | WO2003039346A8 Diagnostics and therapeutics for ocular abnormalities |
| 04/22/2004 | WO2003022202A9 Compositions and methods for treatment of cancer |
| 04/22/2004 | WO2003020893A3 New adenovirus type 7 vectors |
| 04/22/2004 | WO2003020763A9 Soluble t cell receptor |
| 04/22/2004 | WO2002102846A3 Pharmaceutical composition for diagnosis, prevention or treatment of a tumorous state, comprising a modulator of the actin polymerisation state |
| 04/22/2004 | WO2002098362A3 Use of rank antagonists to treat cancer |
| 04/22/2004 | WO2002094852A8 Taci-immunoglobulin fusion proteins |
| 04/22/2004 | WO2002092782A3 Diagnosis and treatment of malignant neoplasms |
| 04/22/2004 | WO2002090567A3 Sperm-specific cation channel, and uses therefor |
| 04/22/2004 | US20040078837 Four human zinc-finger-containing proteins: MDZ3, MDZ4, MDZ7 and MDZ12 |
| 04/22/2004 | US20040077582 Cationic reagents for transfection |
| 04/22/2004 | US20040077578 Inhibition; hybridizing mRNA target; cancer |
| 04/22/2004 | US20040077577 Gene therapy; vaccines; inducing antibodies and/or cytotoxic or helper T lymphocytes |
| 04/22/2004 | US20040077575 Inhibition of pathological angiogenesis in vivo |
| 04/22/2004 | US20040077573 Suppresses overexpression; reducing side effects; such as preventing occurance of plethora while treating anemia with erythropoietin |
| 04/22/2004 | US20040077572 Polynucleotide or complement comprising nucleic acid sequence flanked by first and second inverted repeats |
| 04/22/2004 | US20040077569 Hybridizes with and inhibits expression of nucleic acid molecule encoding alternatively spliced or truncated form; hyperproliferative disorders |
| 04/22/2004 | US20040077568 Inhibitors; oligonucleotides specifically hybridizable with encoding nucleic acids |
| 04/22/2004 | US20040077567 Antisense modulation of CD36 expression |
| 04/22/2004 | US20040077540 Permeabilizing peptide; reversibly enhancing paracellular transport; inhibits homotypic binding |
| 04/22/2004 | US20040077538 Activates patients own factor VII to VIIa; limits thrombin formation |
| 04/22/2004 | US20040077526 SR-BI antagonist and use thereof as contraceptives and in the treatment of steroidal overproduction |
| 04/22/2004 | US20040077051 LSR receptor, its activity, its cloning, and its applications to the diagnosis, prevention and/or treatment of obesity and related risks or complications |
| 04/22/2004 | US20040077029 Human protooncogene and protein encoded therein |
| 04/22/2004 | US20040077011 Novel human gene relating to respiratory diseases and obesity |
| 04/22/2004 | US20040077009 Human cyclin-dependent kinase (hPNQALRE) |
| 04/22/2004 | US20040077002 Useful in the study of vascular smooth muscle cell proliferation and in the treatment of blood vessel diseases that result from excessive smooth muscle cell proliferation, particularly after balloon angioplasty; atherosclerosis |
| 04/22/2004 | US20040077000 Using cynomologous monkey P-glycoprotein nucleic acids and polypeptides in determining bioavailability of drugs and for screening for inhibitors of cynomologous P-glycoprotein |
| 04/22/2004 | US20040076992 Novel cell adhesion molecule specific to activated leukocyte |
| 04/22/2004 | US20040076985 Reagents which regulate human chemokine-like receptor and reagents which bind to human chemokine-like receptor gene products, useful in preventing, ameliorating, or correcting dysfunctions or diseases including HIV infection, |
| 04/22/2004 | US20040076980 Method of separating extra-chromosonal dna from other cellular components |